DCP-001
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for DCP-001, covering 2022-10-10 to 2024-06-17. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment [Phase 1]